Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2011 Financial Results
WALTHAM, Mass., Jul 28, 2011 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the Company will host a conference call at 4:30 p.m.
View HTML
Toggle Summary ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2011 Financial Results and Provides Corporate Update and Fiscal Year 2012 Guidance
Company's Strong Cash Position Supports Aggressive Development of Wholly Owned Product Candidates As Partner Compounds Advance Multiple Compounds Expected to Advance to Next Stage within 12 Months
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentation at the Canaccord Genuity 31st Annual Growth Conference
WALTHAM, Mass., Aug 05, 2011 (BUSINESS WIRE) -- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that its presentation at the Canaccord
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
WALTHAM, Mass., Aug 31, 2011 (GlobeNewswire via COMTEX) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that Company management will
View HTML
Toggle Summary ImmunoGen, Inc. Announces Submission of IND for Wholly Owned Product Candidate for Non-Hodgkin's Lymphoma
IMGN529 is the first IND-stage compound for non-Hodgkin's Lymphoma that provides both anticancer antibody activity and small molecule cancer-killing power
View HTML
Toggle Summary T-DM1 Significantly Improved Progression-Free Survival Compared to Standard of Care for Previously Untreated HER2-Positive Metastatic Breast Cancer
Notable results from Genentech/Roche Phase II trial are featured in conference's official press program T-DM1 utilizes ImmunoGen's Targeted Antibody Payload (TAP) technology with the HER2-targeting trastuzumab (Herceptin(R)) antibody
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentation at the 18th Annual NewsMakers in the Biotech Industry Conference
WALTHAM, Mass., Oct. 13, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc . (Nasdaq:IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that its presentation at the 18 th Annual NewsMakers in the Biotech Industry conference at 10:30 am ET on October 21,
View HTML
Toggle Summary ImmunoGen, Inc. Earns Milestone With Start of SAR3419 Phase II Testing
Event Triggers $3 Million Payment From Sanofi
View HTML
Toggle Summary ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2012 Financial Results
ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2012 Financial Results WALTHAM, Mass., Oct 20, 2011 (BUSINESS WIRE) -- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that the
View HTML
Toggle Summary ImmunoGen, Inc. Reports First Quarter Fiscal Year 2012 Financial Results and Provides Quarterly Update
Lead product candidates have notable developments, while pipeline continues to expand. Recent progress includes positive trastuzumab emtansine (T-DM1) clinical data, advancement of SAR3419 to Phase II testing, progress with lead wholly owned compounds, and advancement of BAY 94-9343 partner
View HTML